Mammographic density as a surrogate endpoint for breast cancer;Mammografisk tetthet som indikator for brystkreftrisiko

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 23, 2003, Pages 3373-3376

  Ursin, Giske ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED DIAGNOSIS; DENSITY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAMMOGRAPHY; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; ADULT; ARTICLE; BREAST TUMOR; FEMALE; MIDDLE AGED; RADIOGRAPHY;

TUMOR MARKER;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1442359540     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
2. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993; 15: 196-208.
3. Wolfe J. Breast patterns as an index of risk for developing breast cancer. AMJ Am J Roentgenol 1976; 126: 1130-9.
4. Gram IT, Funkhouser E, Tabar L. The Tabar classification of mammographic parenchymal patterns. Eur J Radiol 1997; 24: 131-6.
5. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987; 9: 146-74.
6. Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. Am J Radiology 1987; 148: 1087-92.
7. Boyd NF, Byng J, Jong R, Fishell E, Little L, Miller AB et al. Quantitative classification of mammographic densities and breast cancer risks: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670-5.
8. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998; 7: 43-7.
9. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA et al. Mammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst 1995; 87: 1622-9.
10. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003; 12: 332-8.
11. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002; 347: 886-94.
12. Boyd NF, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 2002; 11: 1048-53.
13. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86: 431-6.
14. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9: 110-6.
15. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000; 9: 911-5.
16. Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 2001; 10: 1117-20.
17. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001; 10: 141-2.
18. Ursin G, Spicer DV, Pike MC. Tamoxifen and prevention. Lancet 1993; 341: 693-5.
19. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95: 30-7.
20. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001; 10: 243-8.
21. Byrne C, Hankinson SE, Pollak M, Willett WC, Colditz GA, Speizer FE. Insulin-like growth factors and mammographic density. Growth Horm IGF Res 2000; 10 (suppl A): S24-5.
22. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992; 84: 1170-9.
23. Fabian CJ, Kimler BF, Brady DA, Mayo MS, CH, Ferraro JA et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002; 8: 3105-17.